SCHEDULE: Baillie Gifford Reduces Recursion Pharma Stake Below 5%

Baillie Gifford & Co. reported a 4.6% beneficial ownership in Recursion Pharmaceuticals Class A Common Stock as of December 31, 2025.

Summary

• Baillie Gifford & Co. filed an Amendment No. 6 to Schedule 13G for Recursion Pharmaceuticals, Inc.
• The filing reports beneficial ownership of 23,774,972 shares of Class A Common Stock.
• This represents 4.6% of the Class A Common Stock outstanding.
• Baillie Gifford & Co. holds sole voting power over 23,730,293 shares and sole dispositive power over 23,774,972 shares.
• The shares were acquired in the ordinary course of business and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the reduction in Baillie Gifford's reported stake to below 5%, which could imply a re-evaluation by a major institutional investor.

Positives

• A significant institutional investor, Baillie Gifford & Co., maintains a substantial stake in Recursion Pharmaceuticals, Inc., indicating continued, albeit reduced, confidence.
• The filing confirms the shares were acquired and are held in the ordinary course of business, not for control purposes, suggesting a passive investment strategy.

Negatives

• Baillie Gifford & Co.'s reported beneficial ownership of 4.6% indicates a reduction from a previous stake that would have been 5% or more, as this is an amendment to a Schedule 13G.

Risks

• The filing itself does not detail specific risks related to Recursion Pharmaceuticals, Inc. It is a disclosure of ownership by an investment adviser.

Future Outlook

This filing does not contain forward-looking statements about Recursion Pharmaceuticals, Inc.'s operations or financial performance.

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially from prominent investment advisers like Baillie Gifford, are closely watched in the biotechnology sector. A reduction below the 5% threshold, as indicated by this filing, can sometimes signal a shift in investment strategy or a re-evaluation of the company's prospects relative to peers, though the filing itself does not provide reasons for the change.

Stakeholder Impact

• Shareholders: May view the reduction in a major institutional stake as a negative signal, potentially impacting investor sentiment and share price.

Key Dates

Recommendation

The filing indicates a reduction in a significant institutional investor's stake below the 5% threshold. While this is a negative signal, the filing itself does not provide fundamental reasons for the change in ownership. Investors should hold and monitor further developments and company-specific news before making a definitive buy or sell decision.

Keywords

Recursion Pharmaceuticals, Baillie Gifford, Class A Common Stock, Schedule 13G, Institutional Ownership, Biotechnology, Pharmaceuticals, Investment Adviser